Elena Tóthová
About
In The Last Decade
Elena Tóthová
18 papers receiving 614 citations
Peers
Comparison fields: 5 of 46
- Hematology 556
- Molecular Biology 309
- Genetics 256
- Oncology 220
- Rheumatology 161
Countries citing papers authored by Elena Tóthová
This map shows the geographic impact of Elena Tóthová's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Elena Tóthová with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Elena Tóthová more than expected).
Fields of papers citing papers by Elena Tóthová
This network shows the impact of papers produced by Elena Tóthová. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Elena Tóthová. The network helps show where Elena Tóthová may publish in the future.
Co-authorship network of co-authors of Elena Tóthová
This figure shows the co-authorship network connecting the top 25 collaborators of Elena Tóthová. A scholar is included among the top collaborators of Elena Tóthová based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Elena Tóthová. Elena Tóthová is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | Significance of anemia in patients with CML at diagnosis andduring the treatment with imatinib outside the clinical trials:CAMELIA registry experience | 1 |
| 2 | 2 | |
| 3 | 5 | |
| 4 | 18 | |
| 5 | 21 | |
| 6 | 102 | |
| 7 | 0 | |
| 8 | Reversal of acute renal impairment bybortezomib-doxorubicin-dexamathasone in multiple myeloma.Results from an phase II study | 1 |
| 9 | 0 | |
| 10 | 3 | |
| 11 | 214 | |
| 12 | 148 | |
| 13 | MOŽNOSTI LIEČBY MNOHOPOČETNÉHO MYELÓMU | 0 |
| 14 | 16 | |
| 15 | 8 | |
| 16 | Efficiency of in vivo purging with autologous stem cell transplantation and monoclonal antibody in B-cell lymphomas. | 7 |
| 17 | [New views on the treatment of chronic myelocytic leukemia. Literature review]. | 1 |
| 18 | High expression of Bcl-2 protein in acute myeloid leukemia cells is associated with poor response to chemotherapy. | 52 |
| 19 | P-glycoprotein expression in adult acute myeloid leukemia: correlation with induction treatment outcome. | 8 |
| 20 | [Mixed myelodysplastic and myeloproliferative syndromes]. | 4 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.